After years-long fight, Colorado approves medical marijuana treatment for PTSD
Marijuana for Menstrual Cramps? New York Considers Medical Option
Positive Effects of Medical Marijuana on Alzheimer’s Prevention
A preclinical study published in the Journal of Alzheimer’s Disease found that very small doses of tetrahydrocannabinol (THC), can slow the production of toxic clumps of beta-amyloid proteins in the brain, which are thought to kick start the progression of Alzheimer’s disease.
In a healthy brain, these protein fragments are broken down and eliminated. For those with Alzheimer’s disease, the fragments accumulate to form hard, insoluble plaques.
The study supports the results of previous research that found evidence of the protective effects of cannabinoids, including THC, on patients with neurodegenerative diseases.
Back in 2006, Kim Janda, a chemistry professor at the Scripps Research Institute in La Jolla, California, and his colleagues published the first study showing that THC might have a positive effect in fighting Alzheimer’s.
GW Pharmaceuticals Files for FDA Approval After Report Confirms Success in Treating Epilepsy
GW Pharmaceuticals has chosen the perfect moment to file its cannabis-derived therapy, Epidiolex, with U.S. regulators.
The New England Journal of Medicine just published results from a Phase III study showing that GW’s Epidiolex (derived from cannabidiol) significantly reduced monthly convulsive seizures, especially in children with Dravet syndrome, one of the most difficult types of epilepsy to treat. Children can have dozens, even hundreds, of seizures per month.
GW Pharmaceuticals first reported in March 2016 that CBD-derived Epidiolex cut monthly convulsive seizures by 39 percent in children with Dravet syndrome, but full results of the 120-patient study were only published last week.
Medical marijuana could cost big pharma $4 billion a year
A powerful drug derived from marijuana is on the cusp of federal approval
An experimental drug derived from cannabis to treat epilepsy is on the brink of becoming the first of its kind to win US government approval.
The drug's active ingredient is cannabidiol, the compound in marijuana thought to be responsible for many of its therapeutic effects. Cannabidioldoesn't contain THC, marijuana's main psychoactive ingredient, so it doesn't get users high.
According to results from two large clinical trials released over the past two months, however, cannabidiol does appear to help reduce seizures in two of the hardest-to-treat forms of epilepsy, Lennox-Gastaut Syndrome and Dravet Syndrome.
- 491,634 Views Category: Medical Marijuana
- 404,228 Views Category: Culture
- 319,210 Views Category: Medical Marijuana
- 279,567 Views Category: Fun
- 198,890 Views Category: Odd
- 157,117 Views Category: Fun
- 155,340 Views Category: Videos
- 154,306 Views Category: Nugs
- 150,017 Views Category: News
- 148,962 Views Category: Nugs